Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response

Abstract Previous association results between dopamine D1 receptor (DRD1) rs4532 polymorphism and antipsychotic treatment response in schizophrenia and schizoaffective subjects have been conflicting. Thus, we have conducted a systematic review followed by a meta-analysis. Our results indicated no as...

Full description

Saved in:

Bibliographic Details
Published in:	Psychiatry research Vol. 229; no. 1; pp. 586 - 588
Main Authors:	de Matos, Luiza P.R, Santana, Cinthia V.N, Souza, Renan P
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier Ireland Ltd 30-09-2015
Subjects:	Antipsychotic Agents - therapeutic use Clozapine Clozapine - therapeutic use Female Genetic Predisposition to Disease - epidemiology Genetic Predisposition to Disease - genetics Humans Male Pharmacogenetics Pharmacogenomics Polymorphism, Single Nucleotide - genetics Psychiatry Receptors, Dopamine D1 - genetics Schizophrenia - drug therapy Schizophrenia - epidemiology Schizophrenia - genetics Treatment Outcome Pharmacogenetics Clozapine Pharmacogenomics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Previous association results between dopamine D1 receptor (DRD1) rs4532 polymorphism and antipsychotic treatment response in schizophrenia and schizoaffective subjects have been conflicting. Thus, we have conducted a systematic review followed by a meta-analysis. Our results indicated no association between DRD1 rs4532 polymorphism and overall antipsychotic response or clozapine monotherapy response.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0165-1781 1872-7123
DOI:	10.1016/j.psychres.2015.07.054